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ABSTRACT: Background. Cutaneous head and neck melanoma has poor
outcomes and limited treatment options. In OPTiM, a phase 3 study in patients
with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of
the oncolytic virus talimogene laherparepvec improved durable response rate
(DRR; continuous response 6 months) compared with subcutaneous
granulocyte-macrophage colony-stimulating factor (GM-CSF).
Methods. Retrospective review of OPTiM identified patients with cutaneous
head and neck melanoma given talimogene laherparepvec (n5 61) or GM-
CSF (n5 26). Outcomes were compared between talimogene laherparepvec
and GM-CSF treated patients with cutaneous head and neck melanoma.
Results. DRR was higher for talimogene laherparepvec–treated patients
than for GM-CSF treated patients (36.1% vs 3.8%; p5 .001). A total of
29.5% of patients had a complete response with talimogene laherparepvec
versus 0% with GM-CSF. Among talimogene laherparepvec–treated patients
with a response, the probability of still being in response after 12 months
was 73%. Median overall survival (OS) was 25.2 months for GM-CSF and
had not been reached with talimogene laherparepvec.
Conclusion. Treatment with talimogene laherparepvec was associated
with improved response and survival compared with GM-CSF in patients
with cutaneous head and neck melanoma. VC 2016 The Authors Head &
Neck Published by Wiley Periodicals, Inc. Head Neck 00: 000–000, 2016
KEY WORDS: cutaneous head and neck melanoma, talimogene
laherparepvec, oncolytic virus, cancer immunotherapy
INTRODUCTION
Overall, 15% to 20% of cutaneous melanomas arise from
head and neck locations despite this region representing
<10% of total body surface area.1–3 Outcomes associated
with cutaneous head and neck melanoma are poorer when
compared with all other body sites, with a higher rate of
recurrence and shorter disease-free and overall survival
(OS).1 Surgical treatment of cutaneous head and neck
melanoma is technically challenging, owing to the diffi-
culty in achieving appropriate margins in this cosmeti-
cally sensitive region.4–6 Because of the increased risk of
recurrence and regional and systemic spread and recur-
rence with this location of melanoma, adjuvant therapy
(including radiation therapy) is often used after surgical
resection.7–9 For patients with unresectable head and neck
disease, treatment options have been even more limited,
with radiation therapy frequently used for locoregional
disease control and palliation. Therefore, new treatment
strategies are of high priority.
Oncolytic viruses are novel cancer treatments that
mediate antitumor activity by selectively replicating in
tumors and lysing tumor cells, subsequently releasing
tumor-derived antigens to promote antitumor immunity.10
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Oncolytic viruses can be modified to express genes that
further augment the antitumor immune response.11
Talimogene laherparepvec is a modified herpes simplex
virus (HSV) type-1 designed to specifically replicate in
and lyse tumor cells.12 In addition to modifications
designed to attenuate viral pathogenicity in normal tissues
and to restore antigen presentation by HSV-infected cells,
talimogene laherparepvec is engineered to express the
gene encoding human granulocyte-macrophage colony-
stimulating factor (GM-CSF).12 GM-CSF can act to
recruit and activate antigen-presenting cells to process
and present tumor-derived antigens to help promote tumor
specific T-cell responses.13 Release of immune-
stimulatory viral proteins may further enhance the antitu-
mor immune response.11 Responses in uninjected tumors,
including visceral metastases, have been seen in patients
treated with talimogene laherparepvec (in the OPTiM
study responses to talimogene laherparepvec were
observed in 34% of evaluable uninjected nonvisceral and
15% of evaluable visceral lesions),14–17 indicating that an
effective systemic antitumor response can be achieved.
In the randomized phase 3 OPTiM study, intralesional
talimogene laherparepvec improved the primary endpoint
of durable response rate (DRR; defined as complete
response [CR] or partial response [PR] lasting continu-
ously for 6 months) from 2% to 16% (p< .0001), com-
pared to subcutaneous GM-CSF in patients with stage
IIIB/IIIC/IV melanoma that was not surgically resectable.
The overall response rate (ORR), as evaluated by an inde-
pendent Endpoint Assessment Committee, was also
improved from 6% with GM-CSF to 26% with
talimogene laherparepvec (p< .0001, descriptive). Simi-
larly, 11% of patients had a CR in the talimogene
laherparepvec arm versus <1% in the GM-CSF arm.
Median OS with talimogene laherparepvec treatment was
23.3 months compared with 18.9 months with GM-CSF
treatment (hazard ratio [HR]5 0.79; 95% confidence
interval [CI]5 0.62–1.00; p5 .051).16 At the final
planned analysis of OS, median OS was 23.3 months in
the talimogene laherparepvec arm and 18.9 months in the
GM-CSF arm (HR5 0.79; 95% CI5 0.62–1.00; p5 .049,
descriptive]).18 This article describes a retrospective anal-
ysis of the subgroup of patients from the phase 3 OPTiM
study who had cutaneous head and neck melanoma. DRR,
ORR, time to treatment failure (TTF), and OS are
reported to describe clinical outcomes with talimogene
laherparepvec treatment in this melanoma subtype.
PATIENTS AND METHODS
Study design, patients, and treatment
Eligibility criteria and study design for the randomized,
phase 3, open-label multicenter OPTiM study are summar-
ized in Supplementary Figure S1, online only, and have
been reported in detail previously.16 Briefly, eligible
patients were 18 years old with histologically confirmed
cutaneous injectable and unresectable stage IIIB/IIIC/IV
melanoma. Patients were excluded from the study if they
had 3 or more visceral metastases, except lung metastases
or nodal metastases associated with visceral organs, or vis-
ceral metastases >3 cm. This subgroup analysis included
patients enrolled in the study who, at initial diagnosis, had
melanoma located in the head and neck region (ie, scalp,
face, and neck) as determined by the investigator. Patients
were randomly assigned 2:1 to receive intralesional
talimogene laherparepvec (4 mL initially at 106 pfu/mL,
then after 3 weeks 108 pfu/mL once every 2 weeks) or sub-
cutaneous GM-CSF (125 lg/m2 daily for 14 days in 28-day
cycles). Discontinuation of study treatment because of dis-
ease progression was not required before 24 weeks unless
alternate therapy was required or intolerance to treatment
developed. All patients provided written informed consent,
and all study procedures were approved by institutional
review boards or ethics committees. The trial was registered
with ClinicalTrials.gov (identifier NCT00769704).
DRR was the primary endpoint (defined as the rate of CR
or PR lasting 6 months continuously and beginning within
the first 12 months of treatment). Key secondary endpoints
included OS (time from randomization to death), ORR, onset
TABLE 1. Baseline demographics and clinical characteristics.
Talimogene
laherparepvec GM-CSF
No. of patients N5 61 N5 26
Median (IQR) age, y 70 (61–79) 66 (58–75)
Men, no. (%) 51 (84) 17 (65)
ECOG PS, no. (%)
0 43 (70) 20 (77)
1 18 (30) 6 (23)
Disease stage at screening,* no. (%)
IIIB 9 (15) 5 (19)
IIIC 17 (28) 6 (23)
IVM1a 11 (18) 6 (23)
IVM1b 15 (25) 4 (15)
IVM1c 9 (15) 5 (19)
Elevated LDH, no. (%) 2 (3) 1 (4)
BRAF status,† no. (%)
Mutant 10 (16) 6 (23)
Wild-type 6 (10) 4 (15)
Unknown/missing 45 (74) 16 (62)
Location of first recurrence,‡ no. (%)
Surgical scar (local) 17 (28) 4 (15)
In-transit/satellitosis 21 (34) 7 (27)
Regional lymph node(s) 16 (26) 3 (12)
Distant skin site 7 (11) 6 (23)
Distant lymph node(s) 0 1 (4)
Visceral 3 (5) 2 (8)
Other 4 (7) 4 (15)
Missing 3 (5) 2 (8)
Median (IQR) time from initial
diagnosis to first recurrence, y
0.6 (0.3–1.2) 0.5 (0.3–1.6)
Line of therapy, no. (%)
First line 37 (61) 15 (58)
Second line or greater 24 (39) 11 (42)
HSV-1 status, no. (%)
Seropositive 38 (62) 13 (50)
Seronegative 18 (30) 13 (50)
Unknown 5 (8) 0
Abbreviations: GM-CSF, granulocyte-macrophage colony-stimulating factor; IQR, interquartile
range; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehy-
drogenase; HSV-1, herpes simplex virus type 1.
* Per case report form at screening.
† Because tissue was not collected prospectively, BRAF mutation analysis was reported by
investigators and not evaluated centrally.
‡ Patients may have had more than one site of first recurrence. Site of first recurrence was
evaluated at screening.
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and duration of response, TTF (time from date of randomiza-
tion to the date of the first clinically relevant progressive dis-
ease not followed by response or until death), and safety.
Patients were evaluated clinically every treatment cycle (4 or
5 weeks) and/or radiographically every 12 weeks. DRR and
ORR were determined using modified World Health Organi-
zation Criteria for Tumor Response Evaluation.16,19 Patients
with a best response of CR or PR per investigator assessment
or who had received study treatment for 9 months were
evaluated by an independent blinded endpoint assessment
committee (EAC).
Statistical analysis
Efficacy analyses were done for all patients with cuta-
neous head and neck melanoma who met the criteria for
inclusion in this subgroup analysis and received at least 1
dose of study medication (see Patients above). All analy-
ses were exploratory. The Fisher exact test was used to
compare DRR and ORR between treatment arms. Time-
to-event endpoints were evaluated using Cox proportional
hazard models and unadjusted log-rank tests. DRR and
ORR were based on data from the primary DRR analysis;
data cutoff for this analysis was December 21, 2012. OS
and TTF analyses were based on data from the primary
OS analysis, which was done after 290 survival events
had occurred in the overall study population; the data
cutoff date for this analysis was March 31, 2014. Multi-
variate analysis was conducted to adjust for imbalances in
baseline prognostic factors. Statistical significance was
interpreted at a two-sided 5% confidence level without
multiplicity adjustment.
RESULTS
Patient characteristics, disposition, and treatment
Of the 436 patients enrolled in the OPTiM study, retro-
spective review identified 87 patients (20%) with cutane-
ous head and neck melanoma (treated with talimogene
laherparepvec, n 5 61 [21%]; treated with GM-CSF, n 5
26 [18%]). The baseline clinical characteristics of these
patients are shown in Table 1. Baseline demographics and
characteristics for the intent-to-treat population are shown
in Supplementary Table S1, online only. The median
duration of follow-up at the primary analysis of OS was
35 months (interquartile range [IQR], 13–43 months) for
the talimogene laherparepvec group and 25 months (IQR,
13–39 months) for the GM-CSF group.
Durable and overall response
DRR per EAC was 9.5-times higher in the talimogene
laherparepvec arm (36.1%; 95% CI5 24.2% to 49.4%)
compared to the GM-CSF arm (3.8%; 95% CI5 0.1% to
19.6%; p5 .001). ORR was higher in the talimogene
laherparepvec arm (47.5%; 95% CI 5 34.6% to 60.7%)
FIGURE 1. (A) Representative images from a patient with melanoma of the scalp with metastasis to cervical lymph nodes and liver (stage IVM1c).
The patient was diagnosed 2 years before enrollment in OPTiM and had 2 surgeries: one at diagnosis, and another 1 year after recurrence. Top
row: injection sites shown in yellow arrows at baseline (left panel). Uninjected sites are shown with green dashed arrows. Black dots mark tumor
lesions. Sites included 1 fluorodeoxyglucose (FDG)-avid left upper level V cervical lymph node (center left panel) and 2 FDG-avid liver lesions (cen-
ter right and right panels). Middle row: injections were stopped after complete resolution of scalp lesions after cycle 2 (1 cycle 5 2 injections of
talimogene laherparepvec). Bottom row: Complete resolution of cervical and liver tumors was documented by FDG-PET CT at cycle 7. Patient was
in complete response until the end of the trial, duration of response (complete response) was approximately 17 months.
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than in the GM-CSF arm (7.7%; 95% CI5 1.0% to
25.1%; p5 .0004). Eighteen patients (29.5%) in the
talimogene laherparepvec arm had a CR, whereas no
patient in the GM-CSF arm had a CR. Eleven patients
(18.0%) in the talimogene laherparepvec arm had a PR,
compared with 2 patients (7.7%) in the GM-CSF arm.
DRRs and ORRs were more common among patients
with disease stages IIIB, IIIC, and IVM1a (Supplemen-
tary Table S2, online only). Although ORR was
numerically greater among patients with HSV-
seropositive disease (55.3%; 95% CI5 38.3–71.4) than
patients with HSV-seronegative disease (27.8%; 95%
CI5 9.7–53.5), the difference between the 2 groups
was not statistically significant (p5 .14). Similarly, the
DRR in patients with HSV-seropositive disease (29.4%;
95% CI5 17.5–43.8) was numerically greater but not signif-
icantly different from that in patients with HSV-
seronegative disease (16.1%; 95% CI5 5.5–33.7; p5 .20).
In the talimogene laherparepvec arm, responses were
identified in 63.8% of injected lesions, 7.9% of uninjected
nonvisceral lesions, and 10.8% of visceral lesions. Among
341 responding injected lesions, 311 (91.2%) were cutane-
ous or subcutaneous, and 29 (8.5%) were nodal; among 88
responding uninjected nonvisceral lesions, 65 (73.9%) were
cutaneous or subcutaneous, and 6 (6.8%) were nodal.
Photographs and radiographic images from representative
patients with cutaneous head and neck melanoma who
received treatment with talimogene laherparepvec are
shown in Figures 1 and 2.
Duration of response and probability of responders remain-
ing in response at landmark time points are shown in Figure 3.
Among patients in the talimogene laherparepvec arm with a
response (n5 29), the estimated probability of being in
response after 9 months was 73% (95% CI5 56% to 90%);
this remained unchanged at the 12-month and 15-month time
points.
Time to treatment failure
Median TTF was significantly prolonged for patients in the
talimogene laherparepvec group (18.3 months [IQR, 8.6–not
estimable]) compared with patients in the GM-CSF group (4.1
months [IQR, 2.8–7.4]; HR5 0.32; 95% CI5 0.17–0.61;
p5 .0002). Kaplan–Meier curves for TTF are shown in Figure
4A.
Overall survival and multivariate analysis
Kaplan–Meier curves for primary OS are shown in
Figure 4B. Median OS was not estimable in the
talimogene laherparepvec group (IQR, 29.7 months–not
estimable) and was 25.2 months (IQR, 12.8–37.4 months)
in the GM-CSF group. The unadjusted HR for OS was
0.57 (95% CI5 0.32–1.03) favoring the talimogene
laherparepvec group (unadjusted p5 .062). At 24 and 48
months, estimated survival was 67.2% and 52.9%, respec-
tively, in patients in the talimogene laherparepvec group and
50.0% and 29.6%, respectively, in patients in the GM-CSF
group. To adjust for potential clinically meaningful imbal-
ances in prognostic factors of sex, disease stage, and
Eastern Cooperative Oncology Group (ECOG) perform-
ance status, a multivariate sensitivity analysis was con-
ducted. In this analysis, talimogene laherparepvec
treatment was associated with improved OS compared to
GM-CSF (HR5 0.38; 95% CI 5 0.20–0.72; p5 .003;
Table 2).
DISCUSSION
OPTiM was the first randomized, controlled, phase 3
study with an oncolytic virus to show therapeutic benefit
in melanoma. The study met its primary endpoint, with
the results indicating intralesional talimogene
laherparepvec treatment improved DRR compared to sub-
cutaneous GM-CSF.16 This retrospective analysis of the
OPTiM study evaluated clinical outcomes in the patients
with cutaneous head and neck melanoma cohort and
FIGURE 2. Representative images from a patient with stage IIIC
disease randomized to talimogene laherparepvec who had a
complete response. The patient was enrolled in the study with
desmoplastic melanoma of the forehead with bilateral cervical
fluorodeoxyglucose-avid lymph nodes (left panel). Talimogene
laherparepvec was injected only into the cutaneous lesion
marked by the label (top row). At month 4, a partial response
was reported and injection of talimogene laherparepvec was
stopped. At cycle 6, a complete remission was reported that con-
tinued until the end of the study. Duration of response was 15.5
months. The patient was disease-free at last follow-up contact
approximately 3 years after enrollment.
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FIGURE 3. Duration of response for all
patients with a response per endpoint
assessment committee (EAC) was cen-
sored (marked by arrow) if at the last
tumor assessment there was no evi-
dence (per EAC) that the response had
ended. Probability of being in response
was estimated using the Kaplan–Meier
method. Because only 1 patient in the
granulocyte-macrophage colony-stim-
ulating factor (GM-CSF) group had a
response lasting >3 months, probabil-
ity of being in response was not calcu-
lated for this group.
FIGURE 4. (A) Time to treatment failure per investigator assessment. (B) Overall survival. CI, confidence interval; GM-CSF, granulocyte-macrophage
colony-stimulating factor; IQR, interquartile range; NE, not estimable; OS, overall survival.
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showed that talimogene laherparepvec demonstrated clini-
cal benefit across different outcome measures in this
difficult-to-treat subgroup.
Administration of talimogene laherparepvec was associ-
ated with higher DRR compared to GM-CSF (36.1% vs
3.8%; p< .0001). In addition, responding patients had an
estimated 73% probability of being in response 15 months
or longer. As shown in the representative images (see
Figure 1), some patients receiving talimogene
laherparepvec had resolution of all lesions. The rate of
CR (30%) was noteworthy. Achievement of CR is a par-
ticularly important consideration in patients with cutane-
ous head and neck melanoma because resection of these
often cosmetically disfiguring lesions can be challenging,
and some effective regional treatment options, such as
isolated infusion/perfusion with antitumor agents, are not
feasible for this anatomic site.20
Because retrospective comparisons in general can be
flawed, particularly when comparing groups of patients
that were not prospectively stratified, a multivariate sensi-
tivity analysis that adjusted for imbalances in clinically
important prognostic factors between the treatment arms
in the cutaneous head and neck melanoma subgroup was
performed. This analysis demonstrated a 62% lower risk
of death in patients treated with talimogene laherparepvec
compared with the GM-CSF group (HR5 0.38; 95%
CI5 0.20–0.72; p5 .003). The median OS times in this
retrospective analysis of the cutaneous head and neck
melanoma subgroup are notable, and stand in contrast to
previous reports that have noted poorer survival outcomes
in patients with cutaneous head and neck melanoma.1
Importantly, treatment with talimogene laherparepvec has
been associated with responses at uninjected tumor sites,
including lesions in visceral organs,14,16 indicating that a
systemic antitumor response was initiated.
The better outcomes for patients with cutaneous head
and neck melanoma compared with the overall study popu-
lation are notable. One potential explanation for the better
outcomes observed with talimogene laherparepvec in
patients with cutaneous head and neck melanoma may be
the higher proportion of patients with stage IIIB/IIIC dis-
ease than the overall study population (43% vs 30%). In
an exploratory analysis of OPTiM, patients with stages
IIIB/IIIC/IVM1a melanoma benefited the most from
talimogene laherparepvec, with DRR as high as 33% for
stages IIIB/IIIC and 16% for stage IVM1a, and median
OS that was 41.1 months for patients with stage
IIIB/IIIC/IVM1a disease in the talimogene laherparepvec
arm compared to 21.5 months in the GM-CSF arm
(HR5 0.57; 95% CI 5 0.40–0.80; p< .001 descriptive).16
Recently, a number of new immunotherapy and tar-
geted therapy agents21–27 have been shown to be effective
in patients with advanced melanoma but it is unclear
what proportion of patients receiving these new therapies
in these studies had cutaneous head and neck melanoma.
Given its activity in patients with unresectable melanoma,
its intralesional mode of administration, its ability to
induce durable PRs and CRs, and responses at distant
uninjected sites coupled with the prolonged TTF and OS,
talimogene laherparepvec may represent a potential treat-
ment option for patients with unresectable cutaneous head
and neck melanoma. Notably, talimogene laherparepvec
demonstrated a tolerable safety profile with most adverse
events being within a spectrum of flu-like symptoms, and
generally transient and mild to moderate in severity.16
The key limitation of this study was its retrospective
nature, which did not allow for control of clinical features
across the treatment groups. As noted above, there were
imbalances in duration of median follow-up (1.4-fold lon-
ger for patients treated with talimogene laherparepvec)
and in baseline prognostic factors between arms that may
have influenced the assessment of OS. It is also important
to note that randomization of patients to treatment was
not stratified by tumor location and that, although ran-
domization in the overall population was 2:1 (talimogene
laherparepvec:GM-CSF), fewer patients with cutaneous
head and neck melanoma were randomized to the GM-
CSF arm; the ratio in this analysis was 2.35:1. The influ-
ence on outcomes of this imbalance in randomization is
uncertain.
In conclusion, in this retrospective analysis of the
OPTiM study, administration of talimogene laherparepvec
was associated with improved ORR, DRR, and OS com-
pared to GM-CSF in patients with cutaneous head and
neck melanoma, consistent with results seen in the intent-
to-treat population of the primary study.16 Talimogene
laherparepvec is a potential novel treatment option for
patients with regionally and distantly metastatic unresect-
able cutaneous head and neck melanoma.
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